Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6524
    -0.0011 (-0.17%)
     
  • OIL

    82.69
    +1.34 (+1.65%)
     
  • GOLD

    2,238.80
    +26.10 (+1.18%)
     
  • Bitcoin AUD

    108,771.13
    +2,838.41 (+2.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6038
    +0.0008 (+0.12%)
     
  • AUD/NZD

    1.0901
    +0.0021 (+0.19%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,257.38
    -23.46 (-0.13%)
     
  • FTSE

    7,961.78
    +29.80 (+0.38%)
     
  • Dow Jones

    39,762.64
    +2.56 (+0.01%)
     
  • DAX

    18,488.90
    +11.81 (+0.06%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Abbott spun out its biopharmaceutical segment into a separate company to protect the parent from Humira's impending patent cliff.